Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era-Reference-Cited by-同舟云学术

Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era

Published:2021-06 Issue:3 Volume:4 Page:502-505
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Bellmunt Joaquim,Esteban Emilio,del Muro Xabier García,Sepúlveda Juan Manuel,Maroto Pablo,Gallardo Enrique,del Alba Aranzazu González,Etxaniz Olatz,Guix Marta,Larriba Jose Luis González,Arranz Jose A.,Redrado Miriam,Calvo Alfonso

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference10 articles.

1. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015

2. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019

3. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Motzer;N Engl J Med,2019

4. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update;Sternberg;Eur J Cancer,2013

5. The changing landscape of management of metastatic renal cell carcinoma: current treatment options and future directions;Salgia;Curr Treat Opt Oncol,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring;Cancers;2023-10-11

2. Identification and validation of a novel cuproptosis-related lncRNA gene signature to predict prognosis and immune response in bladder cancer;Discover Oncology;2022-12-01

3. Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma;Journal of Kidney Cancer and VHL;2022-09-29

4. Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis;European Journal of Cancer;2021-09